Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 4 1

Status

Unknown 5Recruiting 5Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 3Tumor-Agnostic 1Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Esophageal Neoplasms 6Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Melanoma 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Leukemia, Myeloid, Acute 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Immune Checkpoint Inhibitors × Clear all
NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4 Recruiting
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06524570 2026-02-18

iFOCUS

UMC Utrecht

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06063681 2025-06-08

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

Stingray Therapeutics

Phase 1 Recruiting
25 enrolled

Neoplasm Metastasis, Recurrence

NCT06472713 2025-01-13

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Sun Yat-sen University

Phase 2 Recruiting
32 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡